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Abstract
Background: Trials are at risk of contamination bias which can occur when participants in the control group are
inadvertently exposed to the intervention. This is a particular risk in rehabilitation studies where it is easy for trial
interventions to be either intentionally or inadvertently adopted in control settings. The Falls in Care Homes (FinCH)
trial is used in this paper as an example of a large randomised controlled trial of a complex intervention to explore the
potential risks of contamination bias. We outline the FinCH trial design, present the potential risks from contamination
bias, and the strategies used in the design of the trial to minimise or mitigate against this. The FinCH trial was a multi-
centre randomised controlled trial, with embedded process evaluation, which evaluated whether systematic training in
the use of the Guide to Action Tool for Care Homes reduced falls in care home residents.
Data were collected from a number of sources to explore contamination in the FinCH trial. Where specific procedures
were adopted to reduce risk of, or mitigate against, contamination, this was recorded. Data were collected from study
e-mails, meetings with clinicians, research assistant and clinician network communications,
and an embedded process evaluation in six intervention care homes.
During the FinCH trial, there were six new falls prevention initiatives implemented outside the study which could have
contaminated our intervention and findings. Methods used to minimise contamination were: cluster randomisation at
the level of care home; engagement with the clinical community to highlight the risks of early adoption; establishing
local collaborators in each site familiar with the local context; signing agreements with NHS falls specialists that they
would maintain confidentiality regarding details of the intervention; opening additional research sites; and by raising
awareness about the importance of contamination in research among participants.
Conclusion: Complex rehabilitation trials are at risk of contamination bias. The potential for contamination bias in
studies can be minimized by strengthening collaboration and dialogue with the clinical community. Researchers
should recognise that clinicians may contaminate a study through lack of research expertise.
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Background
Randomised controlled trials (RCT) are considered one
of the most reliable research methods for evaluating
whether healthcare interventions are effective [1]. The
use of randomisation to allocate participants to the
intervention or control (comparator) ensures that the
baseline characteristics of each group are as similar as
possible [2]. If both groups are treated in exactly the
same way, apart from the intervention they receive, then
any observed differences can be attributed to the inter-
vention. Randomised controlled designs work well if
research protocols are expertly designed and adhered to
but deviation from protocol can lead to introduction of
bias. Randomised controlled trials are only ethically
permissible where there is genuine uncertainty over
whether the intervention is superior. As such, it is
ethical to withhold the intervention from one group of
participants.
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Lewis and Warlow define bias as ‘any departure from
the truth’ [3] and as such the introduction of bias can in-
fluence the findings of a randomised controlled trial.
There are different types of bias that can be introduced
throughout the design and conduct of a randomised
controlled trial. This discussion paper will focus on one
form - contamination bias.
Contamination bias in a randomised controlled trial
can be described as “when members of the ‘control’ group
inadvertently receive the treatment or are exposed to the
intervention” [4]. This may then minimise the difference
in the observed outcomes between the control and
intervention groups. Given the level of investment in
randomised controlled trials to evaluate healthcare inter-
ventions it is important to consider how to manage the
risks of contamination bias to ensure trials can produce
reliable and a robust conclusion to develop clinical prac-
tice. Pragmatic trials where research is delivered in a real
world setting are advantageous in providing evidence of
whether an intervention actually works in routine clinical
settings with wider generalisability and acceptability [5],
however such trials have less control over trial conditions.
The Cochrane group in a systematic review of interven-
tions to prevent falls in care homes identified the need for
researchers to consider the interaction of usual care with
the intervention [6] which could introduce contamination
bias and impact on trial outcomes. There is a concern that
the neutral outcome of rehabilitation trials may be a result
of control participants receiving a diluted version of the
intervention.
Pragmatic trials of complex interventions are particu-
larly at risk of contamination bias because they involve
multiple components, multiple stakeholders and a range
of organisations. This provides multiple opportunities
for either the intervention or control to deviate from
practices stipulated in the research manual. As a conse-
quence, practices in the intervention and control arms
can start to overlap.
The aim of this discussion paper is to provide an under-
standing of the possibilities for contamination bias within
rehabilitation trials which involve a complex intervention,
and to offer insights that might be valuable to researchers
who are conducting such trials. We use the Falls in Care
Homes (FinCH) trial as an example of a large randomised
controlled trial of a complex intervention. We outline the
FinCH trial design, present the potential risks from con-
tamination bias, and the strategies used in the design of
the trial to minimise or mitigate against this. Recommen-
dations for clinicians and researchers are presented.
The falls in care homes (FinCH) experience
The falls in care homes (FinCH) trial
Falls are three times more frequent in care home resi-
dents than in community dwelling older people [7] and
there is currently no conclusive evidence to guide the
management of falls in care home residents [6]. The
Guide to Action Tool for Care Homes is a multifactorial
falls risk assessment and action process that has been
co-designed by clinicians, care home staff, carers and re-
searchers [8]. The assessment and tailored intervention
process is consistent with NICE guidelines for managing
falls in older people [9].
The FinCH trial was a multi-centre randomised
controlled trial, with embedded process evaluation,
evaluating whether systematic care staff training and im-
plementation of the Guide to Action Tool for Care
Homes reduced falls in care home residents. NHS falls
specialists aimed to train 80% of care staff in those care
homes randomly allocated to the intervention arm. The
one-hour standardised training included raising aware-
ness of the importance of managing falls as well as how
to complete the Guide to Action Tool. After training
care staff were advised to complete the Guide to Action
tool with their residents to identify, assess and then take
action to minimise the risk of falls.
Trial recruitment was completed in January 2018 with
87 care homes and 1698 care home residents recruited
across 10 UK sites. Outcome data on the number of
falls, equipment use, medication changes, activities of
daily living, quality of life and primary care visits were
collected at three monthly intervals up to 12months
after randomisation. Further information on the FinCH
trial is available in the published protocol [10].
Potential risks of contamination bias within FinCH
FinCH was a complex rehabilitation trial where the
intervention and trial procedures involved interactions
between clinicians, care homes, residents, researchers
and wider stakeholders, such as commissioners and reg-
ulators of care [11]. These interactions could lead to a
change in behaviour and potentially a change in usual
care, even in control settings where exposure to the
intervention was intended to be prohibited. The poten-
tial risks to introducing contamination bias are sum-
marised in Table 1. It is acknowledged that the points
raised in this discussion article outline potential sources
of contamination bias and whether these sources actu-
ally change behaviours and which sources are more rele-
vant remains unclear.
As part of the FinCH study an embedded process
evaluation was conducted in six care homes to explore
delivery of the intervention, trial processes and the care
home perspective. Data from the process evaluation pro-
vided an insight into the issues of contamination within
the trial and quotes are presented below to highlight the
potential mechanisms for contamination within FinCH.
Clinicians who acted as trainers for the intervention
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were known to the homes due to their NHS clinical
roles:
“And then, when I’m in there, on my other roles,
they’re giving me feedback on what they’ve done and
how they’ve done it, which is really good as well, be-
cause we wouldn’t get that if we, I wasn’t working in
them, so, it’s quite nice to know that they’re actually
cracking on with the … the tool and using it, so,
that’s quite nice.” (NHS Falls specialist delivering
the intervention)
This positive assessment does however highlight that
those delivering the GtACH training (and advocating its
use in this setting) had other roles and responsibilities
which took them across the regional care home sector, in-
cluding to work with care homes randomised not to re-
ceive GtACH. There was potential for practitioners, who
believed in the benefit of the tool, to modify their practice
in line with its recommendations even in control homes:
“I think, I personally really like it. I think it’s a really
good tool. I’m hoping we’ll, it will be around for a
while and we can all use it, because it’s just got such
a very good practical emphasis to it” (NHS Falls spe-
cialist delivering the intervention)
As shown in Table 1, information promoting the re-
search, describing the intervention, or other initiatives
which might impact upon normal care, had a broad
reach with potential to influence practice in the control
arm. Dissemination events can therefore become a
source of contamination when the new way of working
is described to care home managers in order to encour-
age them to participate:
“We went along to a seminar, open event and there
was somebody representing the FiNCH study” (Care
Home Manager (A))
For larger care home chains this is further com-
pounded by the way that companies decide which in-
terventions to use in their homes and the
communication that takes place between homes and
their management teams. Corporate management
could make decisions which modify practice in either
the intervention or control arms.
“We can’t just suddenly decide we’re going to use
a different type of thing, but what we can do is
recommend and put together and put forward
ideas. And say, right, look, this has been really
useful, we should add that to our information, or
Table 1 Potential mechanisms for introducing contamination bias within the FinCH trial
Mechanism for potential risk Potential action impacting on the trial
Detail of the intervention in the study documentation FinCH trial study documentation outlined that the trial was evaluating the
guide to action tool as a way of reducing falls for care homes residents. This
documentation was discussed with care home managers to allow informed
consent. Care home managers could review their existing falls management
strategies and consider using the Guide to Action tool.
NHS clinicians delivering training package to care home staff Falls specialists had access to the confidential training manual which formed
the intervention. Clinicians could share this with other colleagues and care
home staff considering this as best practice. Clinicians may have changed their
behaviour and practice in their day to day clinical practice following their
involvement in the FinCH trial. This might not be a conscious process.
Care home staff and managers move between homes Care home staff that received the FinCH intervention training may move to a
care home in the control arm and share their knowledge and skills. Conversely
skills in the intervention homes could be lost following the training if care staff
leave the home.
Publishing the development of the FinCH intervention and the
feasibility trial
There has been a growing trend to publish trial protocols and development
work to allow transparency in the research process [12]. The development of
the Guide to Action tool was published by the research team and available to
access online. The feasibility trial which established the trial procedures for the
FinCH trial was also published and indicated a positive trend for the
intervention.
Unable to blind therapists, care staff and care home residents to
whether they are allocated to the intervention or control arm
Awareness of the group allocation could influence the response to subjective
outcomes such as the quality of life measures completed by care home staff
and residents.
Promotion of the study findings throughout the duration of the
trial
Researchers are encouraged to engage with a wide range of stakeholders
throughout the research process to maximise impact and to prepare for impact
at the end of the study. The FinCH study was discussed in a wide variety of
forums which included Enabling Research in Care Home (EnRICH) forums, TV
news bulletins, and national conferences, care home communities of practice,
commissioning groups and patient and public involvement groups.
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the information that you’ve got on that form is
much better than what we’re doing, why are we
not using that?” (Care home manager (B))
High staff turnover and changes within management
were highlighted as difficulties for training care staff
in the intervention resulting in potential dilution of
expertise in delivery of the intervention and the po-
tential for staff to move to a care home within the
control group and share their knowledge and skills of
the intervention:
“I think, they’re very busy places, and, but what I
think, from my experience, is that a lot of staff leave
you know, it’s quite fluid from a staffing point of
view.” (NHS Falls specialist delivering the
intervention)
These data highlight that there are multiple risks of
contamination within randomised control trials of
complex interventions and strategies for reducing
contamination are needed throughout the methodo-
logical design.
Strategies used in the design of the FinCH trial
In the design and conduct of the FinCH trial a range of
strategies were used to reduce the potential for contam-
ination bias which are presented in Table 2.
Management of issues throughout the trial
Throughout the trial the study team were made aware of
six clinical initiatives being developed where systematic
training delivered by healthcare professionals in falls
prevention for care homes was planned. These initiatives
included components of the FinCH intervention and
were planned to be delivered in the FinCH study sites,
potentially including homes in the control group. The
FinCH intervention had multiple components and was
developed in line with the best available evidence.
National guidelines included elements of the FinCH
intervention and, therefore as clinical teams develop
their services in line with national guidelines, they were
at risk of introducing contamination.
The strategy for minimising the risk of contamination
was to openly engage with clinical teams and care homes
in order to raise the potential issues of adapting the full
intervention before formal evaluation. By being alert to
Table 2 Strategies used to minimise contamination in FinCH
Mechanism for potential risk Strategies used in FinCH to minimise the risk
Detail of the intervention in the study documentation Discussion by research staff at the set-up meetings about the importance of
continuing with usual care for the control group to act as a comparator.
NHS clinicians delivering training package to care home staff Falls specialists were asked to sign a confidentiality agreement to state that
they wouldn’t share the training manual.
Care home staff and managers move between homes Data on the number of care home staff leaving and starting at each home was
collected to allow discussion of the results in view of this data. It was however
not feasible to collect data on where new staff were joining from and where
staff leaving were going to work, however summarised numbers allowed a
description of the frequency and extent of movement of care home staff.
Publishing the development of the FinCH intervention and the
feasibility trial
The intervention manual was not published prior to the study completion.
Unable to blind therapists, care staff and care home residents to
whether they are allocated to the intervention or control arm
Blinding of research assistants collecting the primary outcome of the number
of falls. The FinCH administrator telephoned care homes prior to the research
assistant visiting to remind the home that the RA should remain blinded to the
group allocation. Cluster randomisation was used at the level of each care
home to ensure that the training and delivery of the Guide to Action Tool was
delivered across the whole home.
Promotion of the study findings throughout the duration of the
trial
Meetings with clinical teams and commissioning groups to emphasise that the
study findings were not yet ready to implement into practice. The content of
the intervention was not described in detail when the study team were invited
to present the on-going trial information and conferences and high profile
impact events.
FinCH intervention developed using best available evidence and
national guidelines
Dialogue with clinical teams who were preparing to deliver the FinCH
intervention in control sites. The study team engaged in discussion with clinical
teams and commissioners regarding the FinCH trial and the risk of delivering
the FinCH intervention in control care homes during the trial. Strategies were
put in place to allow the clinical teams to continue to deliver and develop their
commissioned services in care homes not involved in the FinCH study. The
study team ensured they were offering continued engagement with clinical
teams reporting on the progress of the study, and directing them to current
evidence that was likely to help them to develop strategies to implement their
falls programmes, once the outcome of the FinCH trial was known.
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emerging initiatives, the study team were able to engage
in discussion with the clinical teams and commissioners
to determine how to minimise the impact of the meth-
odological quality of the trial. Clinical teams were en-
couraged and supported to deliver and develop their
commissioned services in care homes not involved in
the FinCH study. Continued engagement included
reporting on the progress of the study as it ran, and
directing clinical teams to current evidence that would
help them implement their falls programmes outside the
context of homes involved in FinCH.
Discussion
Transparency in trials is increasingly important to dem-
onstrate research integrity [12]. However, this transpar-
ency has the potential to create contamination risks [12],
specifically in complex intervention rehabilitation trials
where a network of people are involved in delivering the
intervention [13]. In order to get a trial started and en-
sure recruitment targets are met, engagement with clin-
ical services, health and social care professionals and
commissioners are essential. This dialogue is needed to
raise the profile of the trial and to attract interest in par-
ticipation. While this engagement is important, increas-
ing dialogue, publicity and networking with clinical
teams and commissioners, who may or may not under-
stand the complexities of conducting and achieving a
trusted outcome of a definitive trial, increases the risk of
contamination bias.
The FinCH experience demonstrates the potential for
contamination by presenting studies at public events.
However careful the study team were about revealing
too much of the intervention detail, clinical teams that
were persuaded by the idea of a systematic falls
programme in care homes had an interest in implement-
ing the intervention as soon as possible. The Chief
Investigator of the trial and Principal Investigators in
each of the study sites maintained close contact with
their clinical networks. By doing so, the trial team got to
hear about clinical services and commissioners who were
planning on implementing a similar intervention, with
similar resources, and were able to intervene. It is pos-
sible that research teams which were less clinically con-
nected could have failed to recognise or been unable to
respond to these challenges. The opportunity to talk
with those commissioning and delivering health and so-
cial care, about implementing the intervention prior to
the evidence that it was effective, minimised the poten-
tial risk of contamination bias.
We believe that the FinCH experience is not an iso-
lated one when conducting clinical trials. The need to
clearly describe usual care and consider how it can inter-
act with the intervention has been highlighted by the
Cochrane group in a systematic review of interventions
to prevent falls in care homes [6]. This review identified
poor quality evidence for multifactorial interventions
drawing limited conclusions for practice. Further, high
quality primary research was recommended which con-
sidered the methodological issues of the interaction of
usual care with the intervention group.
Changes to usual care have been reported by clini-
cians in other complex rehabilitation trials such as
the AVERT trial (A Very Early Rehabilitation Trial
for Stroke) [14]. The qualitative process evaluation
identified that, over the years that the trial was run-
ning, some clinicians considered that their routine
care moved towards the early and intensive mobilisa-
tion which was being evaluated in the trial [15]. This
study group have recognised the issue of contamin-
ation bias and are developing methods for monitoring
contamination in complex rehabilitation trials [16].
The gradual change in practice over time which
was seen in AVERT highlights a different aspect of
the potential for contamination bias. In FinCH the
study team had to mitigate against a more sudden
change in practice with commissioners and clinical
services wanting to immediately adapt their practice
to include the FinCH intervention. A gradual shift
and a sudden shift in practice both highlight the need
for a nuanced, observant, responsive and adaptive ap-
proach to communications with research participants
and the health and social care communities with
which they interact.
It is acknowledged that the points raised in this discus-
sion article outline potential sources of contamination
bias and whether these sources actually change behav-
iours and which sources are more relevant remains
unclear.
Recommendations
The following recommendations are based on the learn-
ing from the FinCH experience.
 Identify and monitor potential bias in the conduct of
randomised controlled trials of complex
interventions
 Research teams should strengthen the dialogue with
the clinical community to allow awareness of clinical
developments that could impact on usual care and
the clinical trial outcomes
 Increasing research capacity and capability within
care home staff and social care.
Conclusion
Pragmatic trials of complex interventions are particu-
larly at risk of contamination bias because they in-
volve multiple components, multiple stakeholders and
a range of organisations. The potential risks and
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strategies to mitigate these risks need to be consid-
ered and monitored throughout the trial. The poten-
tial for contamination bias in studies can be
minimized by strengthening collaboration and dia-
logue with the clinical community. Researchers should
recognise that clinicians may contaminate a study
through lack of research expertise.
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